Published in Sci Rep on March 02, 2016
Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity (2007) 12.98
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 4.41
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med (2003) 3.86
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol (2013) 3.53
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell (2014) 3.40
Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol (2007) 3.03
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev (1999) 2.83
The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis (2013) 2.39
16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer (2011) 2.32
Effects of Signal 3 during CD8 T cell priming: Bystander production of IL-12 enhances effector T cell expansion but promotes terminal differentiation. Vaccine (2009) 2.15
Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med (2013) 2.15
Tissue-resident memory T cells. Immunity (2014) 2.04
Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol (2014) 1.94
Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis (2014) 1.92
mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov (2014) 1.87
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84
Antitumor efficacy testing in rodents. J Natl Cancer Inst (2008) 1.80
Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res (2014) 1.63
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54
Tumor immunosurveillance in human cancers. Cancer Metastasis Rev (2011) 1.48
Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res (2015) 1.47
Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst (1997) 1.38
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest (2012) 1.37
Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am (2006) 1.37
Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine (2013) 1.36
Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J Immunol (2015) 1.32
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cutting edge: resident memory CD8 T cells occupy frontline niches in secondary lymphoid organs. J Immunol (2014) 1.22
Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med (2014) 1.21
A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology (2012) 1.20
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res (2012) 1.18
Tissue-resident memory T cells. Immunol Rev (2013) 1.16
Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med (2013) 1.09
Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol (2011) 1.08
The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res (2015) 1.04
A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol (2007) 1.02
A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. Int J Cancer (2011) 0.99
Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int J Cancer (2013) 0.97
Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol (2013) 0.96
Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin Cancer Res (2014) 0.95
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology (2014) 0.95
Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res (2014) 0.94
Optimism over vaccines administered via mucosal surfaces. Lancet (1998) 0.94
Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int J Cancer (2010) 0.94
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother (2013) 0.94
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol (2011) 0.88
Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells. Oncoimmunology (2014) 0.86
Vaccination route matters for mucosal tumors. Sci Transl Med (2013) 0.85
Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge. PLoS One (2014) 0.84
Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. Cancer Immunol Res (2015) 0.83
Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers. Hum Gene Ther (2013) 0.82
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clin Cancer Res (2016) 0.82
Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites. Hum Vaccin Immunother (2014) 0.79
CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation (1993) 0.78
Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment. PLoS One (2014) 0.77
Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines. Clin Cancer Res (2015) 0.76